MMTV-EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone-responsive tissues

Journal of Cellular Biochemistry

Volumn 103, Issue 6, 2008, Pages 2010-2018

  Marozkina, Nadzeya V ^a,b   Stiefel, Steven M ^c   Frierson Jr , Henry F ^a,b   Parsons, Sarah J ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Taconic Anmed   (United States)

Author keywords

Epidermal growth factor receptor; Mammary gland; MMTV promoter; Ovary; Transgenic mice; Uterus

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; STEROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DYSPLASIA; BREAST HYPERPLASIA; BREAST HYPERTROPHY; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; OVARY; OVIDUCT; PRECANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR GENE; TISSUE SECTION; TRANSGENE; UTERUS CARCINOMA; UTERUS HORN; VIRUS CARCINOGENESIS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; NEOPLASMS, HORMONE-DEPENDENT; OVARY; PRECANCEROUS CONDITIONS; PROSTATE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TESTIS; UTERUS;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

EID: 41849094814     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21591     Document Type: Article

References (38)

1. Adamson ED, Wiley LM. 1997. The EGFR gene family in embryonic cell activities. Curr Top Dev Biol 35:71-120.
2. Baselga J, Mendelsohn J. 1994. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29:127-138.
3. Beato M. 1996. Chromatin structure and the regulation of gene expression: Remodeling at the MMTV promoter. J Mol Med 74(12):711-724.
4. Biscardi JS, Tice DA, Parsons SJ. 1999a. C-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 76:61-119.
5. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. 1999b. C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274(12):8335-8343.
6. Boerner JL, Demory ML, Silva C, Parsons SJ. 2004. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 24(16):7059-7071.
7. Brandt R, Eisenbrandt R, Leenders F, Zschiesche W, Binas B, Juergensen C, Theuring F. 2000. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 19(17):2129-2137.
8. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk M, Zwijsen A. 1999. Smad5 knockout mice die at midgestation due to multiple embryonic and extraembryonic defects. Development 126(8):1631-1642.
9. Chepko G, Slack R, Carbott D, Khan S, Steadman L, Dickson RB. 2005. Differential alteration of stem and other cell populations in ducts and lobules of TGFalpha and c-Myc transgenic mouse mammary epithelium. Tissue Cell 37(5):393-412.
10. Chrysogelos SA, Dickson RB. 1994. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 29(1):29-40.
11. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. 2002. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8:3438-3444.
12. Ejskjaer K, Sorensen BS, Poulsen SS, Mogensen O, Forman A, Nexo E. 2005. Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Mol Hum Reprod 11(8):543-551.
13. Hinrichs SH, Fontes JD, Bills ND, Schneider PD. 1991. Transgenic models of human cancer. Princess Takamatsu Symp 22:259-274.
14. Hunter T. 2000. Signaling - 2000 and beyond. Cell 100(1):113-127.
15. Ishizawar R, Parsons SJ. 2004. C-Src and cooperating partners in human cancer. Cancer Cell 6(3):209-214.
16. Jamnongjit M, Gill A, Hammes SR. 2005. Epidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturation. Proc Natl Acad Sci USA 102(45):16257-16262.
17. Jasonni VM, La Marca A, Santini D. 2005. Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium. Int J Gynaecol Obstet 89(3):297-298.
18. Jhappan C, Stahle C, Harkins RN, Fauste N, Smith GH, Merlino GT. 1990. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61(6):1137-1146.
19. Kaminski R, Zagozdzon R, Fu Y, Mroz P, Fu W, Seng S, Avraham S, Avraham HK. 2006. Role of SRC kinases in Neu-induced tumorigenesis: Challenging the paradigm using Csk homologous kinase transgenic ice. Cancer Res 66(11):5757-5762.
20. Krane IM, Leder P. 1996. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12:1781-1788.
21. Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA. 2005. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 24(33):5173-5190.
22. Lo HW, Hsu SC, Hung MC. 2006. EGFR signaling pathway in breast cancers: From traditional signal transcution to direct nuclear translocalization. Breast Cancer Res Treat 95(3):211-218.
23. Moller P, Mechtersheimer G, Kaufmann M, Moldenhauer G, Momburg F, Mattfeldt T, Otto HF. 1989. Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast. Pathol Anat Histopathol 414(2):157-164.
24. Muller WJ. 1991. Expression of activated oncogenes in the murine mammary gland: Transgenic models for human breast cancer. Cancer Met Rev 10:217-227.
25. Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, Cardiff RD, Meise KS, Li F, Halter SA, Coffey RJ. 1996. Synergistic interaction of the Neu proto-oncongene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16(10):5726-5736.
26. Olayioye MA, Neve RM, Lane HA, Hynes NE. 2000. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19(13):3159-3167.
27. Pearson-White S. 1993. Snol, a novel alternatively spliced isoform of the ski proto-oncogene homolog, sno. Nucleic Acids Res 21(19):4632-4638.
28. Ruibal A, Garrido-Pumar M, Arias JI. 2006. Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers. Rev esp Med Nucl 25(1):15-19.
29. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. 1987. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1(8547):1398-1402.
30. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
31. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103(2):211-225.
32. Siegel PM, Dankort DL, Hardy WR, Muller WJ. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14(11):7068-7077.
33. Solbach C, Roller M, Nicolettri M, Budischewski K, Knecht R, Kaufmann M. 2005. Cancer of the uterine cervix is susceptible to anti-EGF-R antibody EMD 55,900 therapy. Anticancer Res 25(6B):4261-4267.
34. Velu TJ, Vass WC, Lowy DR, Beguinot L. 1989. Functional heterogeneity of proto-oncogene tyrosine kinases: The C terminus of the human epidermal growth factor receptor facilitates cell proliferation. Mol Cell Biol 9(4):1772-1778.
35. Wiesen JF, Young P, Werb Z, Cunha GR. 1999. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 126(2):335-344.
36. Wilding G, Patrick Soulie P, Trump D, Das-Gupta A, Small E. 2006. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 106(9):1917-1924.
37. Wong KH, Wintch HD, Capechhi MR. 2004. Hoxall regulates stromal cell death and proliferation during neonatal uterine development. Mol Endocrinol 18(1):184-193.
38. Zeineldin R, Hudson LG. 2006. Epithelial cell migration in response to epidermal growth factor. Methods Mol Biol 327:147-158.